Aditxt Inc Ordinary Shares ADTX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ADTX is a good fit for your portfolio.
News
-
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
-
Aditxt Signs Second Amendment to the Arrangement Agreement with Appili Therapeutics, Targeting September 30 Closing of the Acquisition
-
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
-
Aditxt and Evofem Amend and Restate Merger Agreement, Targeting September 30 Closing
-
Hello Alpha Partners with Evofem to Offer Phexxi® as a Hormone-Free Contraception Solution on its Platform for Women's Healthcare
-
Evofem Biosciences Announces Financial Results for the First Quarter of 2024
-
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
Trading Information
- Previous Close Price
- $1.38
- Day Range
- $1.31–1.44
- 52-Week Range
- $1.30–68.08
- Bid/Ask
- $1.35 / $1.43
- Market Cap
- $2.69 Mil
- Volume/Avg
- 185,532 / 596,968
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.81
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics the way bodies naturally induce tolerance to tissues.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 47
- Website
- https://www.aditxt.com
Valuation
|
Metric
|
ADTX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.23 |
Price/Sales | 0.81 |
Price/Cash Flow | — |
Price/Earnings
ADTX
Financial Strength
|
Metric
|
ADTX
|
|---|---|
Quick Ratio | 0.03 |
Current Ratio | 0.09 |
Interest Coverage | −3.44 |
Quick Ratio
ADTX
Profitability
|
Metric
|
ADTX
|
|---|---|
Return on Assets (Normalized) | −174.88% |
Return on Equity (Normalized) | −931.72% |
Return on Invested Capital (Normalized) | −201.46% |
Return on Assets
ADTX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Hqjqysyb | Pqdk | $565.6 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Vrzjgpk | Mxqfnk | $127.8 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Nptrdhlkz | Lcptht | $118.7 Bil | |||
| Moderna Inc
MRNA
| Tfscbmh | Wpvm | $46.8 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Qbqmmkqv | Tdmkr | $29.7 Bil | |||
| argenx SE ADR
ARGX
| Rtstpqbv | Znn | $29.3 Bil | |||
| BioNTech SE ADR
BNTX
| Jnblyrlx | Mcjwn | $20.7 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Vqljctgd | Hbdmzq | $16.1 Bil | |||
| United Therapeutics Corp
UTHR
| Kgttsvr | Rpd | $15.0 Bil | |||
| Incyte Corp
INCY
| Jhmjjhwkx | Ryrrd | $13.5 Bil |